Table 4.

Prior and incident cancers, clinical table^*

			Prior cancer		Incident cancer
Cohort and patient number	Age band, years	Sex	Site of prior cancer	Time preregistration, years	Site of incident cancer	Definite/probable/ possible	Time postregistration, years
Anti-TNF cohort
1	60–69	Female	Lung	0.5	Spinal and liver metastases	Definite	0.9
2	40–49	Female	Melanoma	2.9	CNS metastases	Probable	0.5
3	50–59	Male	Melanoma	3.5
First incident cancer					Bladder	Definite	2.4
Second incident cancer					Pleural melanoma	Definite	3.9
4	50–59	Female	Breast	4.6	Neck lump	Probable	2.6
5	60–69	Female	Melanoma	7.5	Multiple metastases (adenocarcinoma)	Definite	3.1
6	50–59	Female	Digestive organ	8.9	Colon	Definite	1.0
7	60–69	Male	Cecum	10.3	Colon	Definite	0.9
8	70–79	Female	Breast	10.9	Colon	Definite	2.6
9	60–69	Female	Kidney	12.8	Kidney with spread to inferior vena cava	Probable	2.5
10	60–69	Female	Breast	15.3
First incident cancer					Low-grade CLL	Definite	2.7
Second incident cancer					Lung with liver metastases	Definite	2.9
11	70–79	Female	Appendix adenocarcinoma	21	Cholangiocarcinoma	Definite	0.05
DMARD cohort
12	70–79	Male	Prostate	2.6	Prostate with bony metastases	Probable	1.9
13	50–59	Female	Uterus	4.7	Frontal lobe of brain	Definite	1.0
14	60–69	Female	Breast	5.4	Pancreatic adenocarcinoma with pleural and peritoneal metastases	Definite	0.5
15	60–69	Male	Prepuce	5.9	Penis with metastases	Probable	2.8
16	50–59	Female	Breast	8.6	Anal	Definite	1.6
17	50–59	Female	Thyroid	9.7	Kidney	Definite	1.4
18	70–79	Male	Kidney	9.7	Transitional cell carcinoma of bladder	Definite	2.1
19	60–69	Female	Breast	10.6	Breast with liver and bone metastases	Probable	2.8
20	70–79	Male	Lip	15.2	Lung	Definite	2.0

^*Anti-TNF = anti–tumor necrosis factor; CNS = central nervous system; CLL = chronic lymphocytic leukemia; DMARD = disease-modifying antirheumatic drug.